NCT02021500

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: Celgene · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.

Detailed description

A study to collect survival status of CA046 subjects who were know to be alive at the last report of vital status for CA046 - approximate timeframe - end of March, 2013. Once consent is given, on a quarterly basis, information on status will be collected to include: * Vital Status * Date of disease progression * Subsequent anticancer therapy for pancreatic adenocarcinoma

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	ABI-007	No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)

Timeline

• Start date: 2014-01-02
• Primary completion: 2015-04-16
• Completion: 2015-04-16
• First posted: 2013-12-27
• Last updated: 2019-11-01

Locations

39 sites across 9 countries: United States, Australia, Austria, Canada, France, Germany, Italy, Spain, Ukraine